By Healthcare Dive Staff | May 27, 2026
In a move signaling a renewed focus on complex healthcare integration and margin expansion, global pharmaceutical distributor Cencora announced on Wednesday that industry veteran Eva Boratto will assume the role of Executive Vice President and Chief Financial Officer. Boratto, who most recently served as the CFO of retail giant Bath & Body Works, is set to join the company at the end of June.
The appointment marks a significant transition for the Pennsylvania-based distributor, as Boratto steps into the shoes of long-time finance chief James Cleary. Cleary, who previously announced his intent to retire, will remain with the organization in an advisory capacity through the end of the year to ensure a seamless transition of the financial helm.
The Professional Trajectory of Eva Boratto
Eva Boratto’s appointment is widely viewed by analysts as a strategic "homecoming" to the healthcare sector, where she spent the vast majority of her career. Before her tenure at Bath & Body Works, Boratto was a central figure at CVS Health, where she spent over a decade ascending through the ranks of the enterprise’s financial leadership.
Her time at CVS was marked by high-stakes transformations. She served as the CFO of Caremark, the company’s influential pharmacy benefit manager (PBM), before transitioning to the role of chief accounting officer and eventually rising to CFO of the entire CVS Health enterprise from 2018 to 2021. This period was defined by the massive $69 billion acquisition and integration of the insurance giant Aetna—a deal that fundamentally reshaped the American healthcare landscape.
Prior to her CVS tenure, Boratto honed her expertise in the pharmaceutical sector through a two-decade-long career at the drug manufacturer Merck. This deep-rooted history in both drug production and retail pharmacy distribution makes her uniquely qualified to navigate Cencora’s complex ecosystem, which sits at the critical intersection of manufacturers, providers, and patients.
Chronology of the Transition
The transition process has been carefully orchestrated to maintain investor confidence and operational stability:
- Early 2026: James Cleary announces his retirement from Cencora after a successful tenure as CFO.
- May 6, 2026: Cencora releases its quarterly results, noting revenue growth despite market pressures and rising costs, while reaffirming annual profit forecasts.
- May 27, 2026: Cencora officially announces the appointment of Eva Boratto as the new EVP and CFO.
- Late June 2026: Boratto is scheduled to officially commence her role at Cencora.
- Year-End 2026: James Cleary is slated to conclude his advisory role, completing the leadership handover.
Strategic Implications: Why Boratto?
The decision to hire Boratto comes at a pivotal time for Cencora. While the company has enjoyed sustained revenue growth, it is currently grappling with shifting market dynamics. Manufacturers are increasingly aggressive in pricing strategies, and brand-name drug margins are facing compression.
Leerink Partners analyst Michael Cherny noted that the appointment serves as an "uncertainty eliminator." For investors, the departure of a long-standing CFO like Cleary can often introduce volatility. By bringing in someone with Boratto’s specific experience in integrating multi-billion dollar mergers, Cencora is signaling to the street that it is prepared for its next phase of growth.
"Her time as CFO at CVS was during a period of incredible complexity," Cherny wrote in a research note. "Stepping into the Cencora role should be relatively straightforward by comparison, allowing her to focus immediately on operational efficiency and the integration of the company’s recent aggressive acquisition spree."
Supporting Data and the Pivot to Specialty Services
Cencora’s growth strategy has shifted significantly over the past 18 months, moving away from a reliance on traditional drug distribution toward higher-margin specialty services. The company has deployed roughly $10 billion in capital to pivot its business model, including:
- Retina Consultants of America: Acquiring a majority stake in this management services organization to bolster its presence in specialized eye care.
- OneOncology: A multi-billion dollar investment in a cancer care platform, positioning Cencora as a vital partner in the growing oncology market.
- EyeSouth Partners: The acquisition of the retina business from EyeSouth, further consolidating its footprint in specialty sub-sectors.
These acquisitions are designed to insulate the company from the volatility of the retail pharmaceutical market. By controlling the supply chain for complex, high-cost specialty drugs, Cencora can command better margins and provide more comprehensive value-added services to providers and patients alike.
Official Responses and Financial Guidance
Cencora CEO Robert Mauch praised the appointment, highlighting Boratto’s specific blend of talents. "Eva brings deep healthcare expertise and a proven track record of leading complex, global finance organizations," Mauch stated in the press release. "Her leadership will be instrumental as we continue to execute our strategy of expanding our specialty services and driving sustainable, long-term value for our shareholders."
Alongside the announcement of the leadership change, Cencora moved to reassure the market regarding its financial health. The company reaffirmed its 2026 guidance, projecting adjusted diluted earnings per share (EPS) to fall between $17.70 and $17.90. Furthermore, the company maintained its long-term outlook, targeting earnings growth of 10% to 14%.
Future Outlook: What to Expect
As Boratto prepares to take the reins, the primary question among industry observers is how she will approach the company’s capital allocation and operational forecasting. While Cleary oversaw a period of significant expansion, Boratto’s mandate will likely involve optimizing the integration of the $10 billion in recent acquisitions.
The "specialty" pivot is not without risk. Integrating disparate platforms like OneOncology and various retina practices requires sophisticated financial oversight and a keen understanding of provider-side economics—an area where Boratto’s previous experience with Aetna’s provider networks will be invaluable.
Furthermore, as the healthcare industry faces ongoing scrutiny regarding drug pricing and PBM transparency, Boratto’s background—which includes experience on the PBM side at CVS Caremark—will likely be a strategic asset. She understands the levers that drive profitability in the distribution chain, which could provide Cencora with a competitive edge as they negotiate with both pharmaceutical manufacturers and healthcare providers.
Conclusion
The appointment of Eva Boratto is more than just a C-suite replacement; it is a calculated move to reinforce Cencora’s position as a dominant player in the specialty drug distribution market. By securing an executive with a demonstrated history of navigating the "incredible complexity" of modern healthcare, Cencora is positioning itself to weather the current market pressures while capitalizing on the higher-margin potential of its recent investments.
As the company enters the second half of 2026, all eyes will be on the synergy between Boratto’s financial stewardship and the operational realities of a company that is rapidly evolving from a traditional distributor into a comprehensive healthcare services platform. The transition of James Cleary to an advisory role provides the necessary continuity, but the era of Eva Boratto promises a new chapter of strategic refinement and, potentially, further expansion into the specialized clinical services sector.
For shareholders, the guidance reaffirmation and the high-profile hire serve as a dual-layer of stability in an otherwise volatile healthcare landscape. The challenge ahead for Boratto will be to prove that the company’s recent multi-billion dollar bets on oncology and specialty eye care can deliver the consistent, high-margin returns that the market now expects from a global leader in the pharmaceutical supply chain.
